Severe asthma patients on oral corticosteroid therapy as a distinct phenotype: The european U-BIOPRED cohort

Rationale: A relatively important proportion of patients with severe asthma end up using a daily dose of oral corticosteroids (OCS) in addition to their high dose of inhaled corticosteroids (ICS). We have determined whether oral CS-dependent severe asthma is a distinct phenotype from those only on ICS. Methods: Participants were recruited from adult pulmonary clinics across Europe and severe asthma diagnosed according to IMI-criteria (Bel et al. Thorax 2011). They had either uncontrolled asthma as defined by the GINA guidelines AND/OR two or more severe exacerbations in the past 12 months. Asthma diagnosis was confirmed by a history of typical symptoms and either reversibility in FEV1 of >=12% and 200ml after 400 T-test, Mann Whitney U test and Chi-square test were used. Results: In the 374 severe asthma participants, 167 (44%) were on oral prednisolone. The oral prednisolone group was older but had similar FEV1 (% predicted) and BMI. There was a lower rate of cigarette smoking with lower proportion of current smokers and never-smokers, but a higher percentage with nasal polyps. There was no difference in atopy as measured by skin prick tests or RAST IgE. A higher proportion of patients had 2 or more exacerbations per year (68.3% vs 56.4%; p=0.02). A greater proportion of patients were using MDI and nebulised short-acting b-agonists and theophylline. Exhaled NO was raised (31 ppb vs 22 ppb; p=3% and neutrophils>=65%, there was a greater proportion of eosinophilic (38% vs 30%) and of mixed granulocytic (23% vs 5%), at the expense of lower paucigranulocytic (14% vs 41%)(Chi-square: p